Triple negative breast cancers as well as serous ovarian cancers, which almost exclusively harbor p53 mutations, are often initially sensitive to therapy such as cis-platin drugs (Luvero et al., 2014; Wahba and El-Hadaad, 2015), which cause replication stalling. This evidence concerns the gene TP53 and breast carcinoma.